Evidence map›Paper›PMID 34815696›Full record

ArticleInternational journal of general medicine2021

Age- and Gender-Independent Association of

Ezeldine K Abdalhabib, Denise E Jackson, Badr Alzahrani, Elyasa Elfaki, Alneil Hamza, Abdelbaset Mohamed Elasbali, Fehaid Alanazi, Abdulrahman Algarni, Ibrahim Khider Ibrahim, Muhammad Saboor

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of general medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact, top 76% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it, 0 citations in OpenAlex.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 3 countries.

Ezeldine K AbdalhabibDepartment of Clinical Laboratory Sciences, College of Applied Medical Sciences, AlQurayyat, Jouf University, Sakaka, Saudi Arabia.
Denise E JacksonThrombosis and Vascular Diseases Laboratory, School of Health and Biomedical Sciences, RMIT University, Victoria, Australia.ORCID 0000-0001-9044-8009
Badr AlzahraniDepartment of Clinical Laboratory Sciences, College of Applied Medical Sciences, AlQurayyat, Jouf University, Sakaka, Saudi Arabia.
Elyasa ElfakiDepartment of Clinical Laboratory Sciences, College of Applied Medical Sciences, AlQurayyat, Jouf University, Sakaka, Saudi Arabia.
Alneil HamzaDepartment of Clinical Laboratory Sciences, College of Applied Medical Sciences, AlQurayyat, Jouf University, Sakaka, Saudi Arabia.
Abdelbaset Mohamed ElasbaliDepartment of Clinical Laboratory Sciences, College of Applied Medical Sciences, AlQurayyat, Jouf University, Sakaka, Saudi Arabia.ORCID 0000-0002-7003-9846
Fehaid AlanaziDepartment of Clinical Laboratory Sciences, College of Applied Medical Sciences, AlQurayyat, Jouf University, Sakaka, Saudi Arabia.
Abdulrahman AlgarniDepartment of Medical Laboratory Technology, College of Applied Medical Sciences, Northern Borders University, Arar, Saudi Arabia.ORCID 0000-0001-9184-269X
Ibrahim Khider IbrahimDepartment of Hematology, Faculty of Medical Laboratory Sciences, Al Neelain University, Khartoum, Sudan.ORCID 0000-0002-8223-5369
Muhammad SaboorDepartment of Medical Laboratory Technology, Faculty of Applied Medical Sciences, Jazan University, Jazan, Saudi Arabia.ORCID 0000-0002-2901-0216
Jouf University · SAAl-Neelain University · SDJazan University · SANorthern Border University · SARMIT University · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeDNA damage to hematopoietic progenitor cells is an essential factor for leukemia development as a failure of the host DNA repair system to fix errors in DNA. This study aimed to assess the association of PATIENTS AND

methodsThe present study was conducted on 186 newly diagnosed patients with CML, aged 19-70 years (118 males and 68 females; mean age of 46.15±13.91 years) and 186 normal healthy controls (123 males and 63 females; mean age of 44.94±8.97 years). Polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) assay was utilized to analyze the

resultsThe genotypic frequencies of Arg399Gln polymorphism in cases were 131 (70.4%) homozygous Arg/Arg, 46 (24.7%) homozygous Gln/Gln, and 9 (4.8%) heterozygous Arg/Gln as compared to the controls ie, 153 (82.3%), 73 (14.5%), and 6 (3.2%), respectively. The Arg399Gln variant genotypic frequencies significantly differed between the cases and controls (

conclusion

Indexed as

chronic myeloid leukemiapolymorphismXCCR1

Identifiers

PMID34815696
PMCPMC8605866
OpenAlexW3214266172

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.